MedTrace Logo

Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children

NCT02328768 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2024-01-09

No results posted yet for this study

Summary

The overall purpose of this study is to determine if replacing standard soybean oil based fat emulsions with Omegaven®, a fish oil based fat emulsion, can reverse or prevent the progression of parenteral nutrition associated liver disease. It is a compassionate use protocol for patients who already have significant liver disease related to parenteral nutrition.

Conditions

  • Total Parenteral Nutrition-Induced Cholestasis

Interventions

DRUG

Omegaven

Sponsors & Collaborators

  • Children's Hospital and Medical Center, Omaha, Nebraska

    collaborator OTHER

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Brian A Jones, MD · University of Nebraska Medical Center/Children's Hospital & Medical Center

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02328768 on ClinicalTrials.gov